



SHUKRA

PHARMACEUTICALS LTD.

30th December, 2023

To,
The General Manager-Listing
Corporate Relationship Department
The BSE Limited
Ground Floor, PJ Towers,
Dalal Street, Mumbai-400001

Scrip Code: 524632

Dear Sir/Madam,

Subject: Intimation for Closure of Trading Window for the Quarter Ended December 31, 2023.

This is to inform you that the Company is closing its Trading window for dealing in the securities of the Company by the Promoters, members of the Promoter Group, Directors, KMPs, Insiders, Designated and Connected persons and their immediate relatives from Monday, January 1, 2024 till 48 hours after the declaration of its Unaudited Financial Results for the Quarter ended December 31, 2023 pursuant to the provisions of the Clause 4(2) of Schedule B read with Regulation 9 of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (as amended from time to time) and SEBI Circular No. SEBI/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated August 5, 2022 and SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated July 19, 2023 read with Company's "Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading in Securities by Designated Persons" ("Insider Trading Code").

Accordingly, all the Designated persons (including dependants and immediate relatives as per code) and connected persons are advised not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of trading window.

The date of the Board Meeting in connection with publishing its Unaudited Financial Results for the quarter ended December 31, 2023 will be announced in due course.

You are requested to take the same on record.

Thanking You.
Yours Faithfully,

For Shukra Pharmaceuticals Limited

Bhoomi Patel
Director
DIN: 08316893



CIN : L24231GJ1993PLC019079